Neuroptis Biotech announces the preclinical results for its dry eye product ML7
Neuroptis Biotech, the ophthalmology drug research and development specialist, announces positive results in preclinical trials of the eye-drop formulation of its ML7 product. ML7 is intended for use in the treatment of eye surface diseases, particularly dry eye. The candidate molecule, ML7, is the first in a new therapeutic class.